Photo of Prof Andrew Pettitt

Prof Andrew Pettitt MA, MB BChir, PhD, MRCP, FRCPath

Ronald Finn Professor of Experimental Medicine and Honorary Consultant Haematologist (Clatterbridge Cancer Centre) Molecular and Clinical Cancer Medicine

Research

Therapy resistance in CLL and lymphoma

Andrew’s laboratory research is focused on therapy resistance in chronic lymphocytic leukaemia (CLL) and led to the first trial in cancer to show that patients with TP53 inactivation benefit from drugs that work through p53-independent mechanisms (J Clin Oncol 2012;30:1647-55). A longstanding Bloodwise and CR-UK grant-holder, Andrew is currently leading three phase III NIHR portfolio studies comparing alternative frontline treatment approaches in CLL and lymphoma and has established national sample collections for these diseases to drive and facilitate correlative and translational science. These include the UK CLL Trials Biobank which was pivotal to a major investment by Genomics England Ltd (GEL) to perform whole genome sequencing of CLL trial samples as one of 3 Pilots for the GEL 100K Genomes Project. Andrew is part of a national consortium tasked with harnessing the full scientific potential of this unique resource.